
IRON Stock Forecast & Price Target
IRON Analyst Ratings
Bulls say
Disc Medicine Inc. has seen an increase in its probability of success for bitopertin's FDA approval to 100%, reflecting strong confidence in its clinical trials demonstrating significant efficacy. The company also holds promising potential for its other candidate, DISC-0974, with analysts suggesting a favorable risk/reward profile stemming from expected Phase 2 data in myelofibrosis-related anemia. These positive developments, combined with a revised price target of $114 based on comprehensive assessments and an expedited timeline for the bitopertin launch, position Disc Medicine as a compelling investment opportunity in the biopharmaceutical sector.
Bears say
Disc Medicine Inc faces a negative outlook primarily due to concerns surrounding the efficacy and safety of its lead asset, bitopertin, which may not yield statistically significant treatment benefits in its Phase 3 trial, leading to potential setbacks in regulatory approval. Furthermore, there are indications that the commercial opportunities for bitopertin in erythropoietic protoporphyria (EPP) and X-linked protoporphyria (XLP) could be more limited than previously anticipated, with no strong analogs for comparison. Additionally, the company operates with constrained cash reserves, raising the risk of needing additional funding to support its development pipeline, which could further impact its financial stability and market position.
This aggregate rating is based on analysts' research of Disc Medicine Inc and is not a guaranteed prediction by Public.com or investment advice.
IRON Analyst Forecast & Price Prediction
Start investing in IRON
Order type
Buy in
Order amount
Est. shares
0 shares